Search results for "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma"

showing 5 items of 5 documents

Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice.

2014

Therapeutic natural killer (NK)-cell-mediated alloreactivity toward acute myeloid leukemia has largely been attributed to mismatches between killer immunoglobulin-like receptors (KIRs) on NK cells and their ligands, HLA class I molecules, on target cells. While adult acute B-cell precursor leukemia (BCP-ALL) appears to be resistant to NK-cell-mediated lysis, recent data indicate that pediatric BCP-ALL might yet be a target of NK cells. In this study, we demonstrate in a donor-patient-specific NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate considerable alloreactivity toward pediatric BCP-ALL in vivo. Notably, both adoptively transferred mature KIR(+)…

Cytotoxicity ImmunologicGenotypeXenotransplantationmedicine.medical_treatmentImmunologyTransplantation HeterologousAntineoplastic AgentsGraft vs Leukemia EffectHuman leukocyte antigenBiochemistryMiceImmune systemReceptors KIRMice Inbred NODPrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAnimalsHumansChildB cellSevere combined immunodeficiencybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaCell BiologyHematologyDNA Methylationmedicine.diseasePrognosisTransplantationKiller Cells NaturalLeukemiaDisease Models Animalmedicine.anatomical_structureImmunologyAzacitidineCytokinesInterleukin-2businessBlood
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic proge…

2001

Stromal cell-derived factor-1alpha (SDF-1alpha) is a potent chemoattractant for hematopoietic progenitor cells (HPC), suggesting that it could play an important role during their migration within or to the bone marrow (BM). The integrin VLA-4 mediates HPC adhesion to BM stroma by interacting with CS-1/fibronectin and VCAM-1. It is required during hematopoiesis and homing of HPC to the BM. As HPC migration in response to SDF-1alpha might require dynamic regulation of integrin function, we investigated if SDF-1alpha could modulate VLA-4 function on BM CD34(hi) cells.CD34(hi) BM cells and hematopoietic cell lines were tested for the effect of SDF-1alpha on VLA-4-dependent adhesion to CS-1/fibr…

Cancer ResearchIntegrinsReceptors CXCR4Stromal cellIntegrinCD34Receptors Lymphocyte HomingVascular Cell Adhesion Molecule-1Bone Marrow CellsIntegrin alpha4beta1Hematopoietic Cell Growth FactorsCell LineColony-Forming Units Assaychemistry.chemical_compoundMiceLeukemia Megakaryoblastic AcutePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGeneticsCell AdhesionTumor Cells CulturedAnimalsHumansVCAM-1Cell adhesionMolecular BiologybiologyChemotaxisVLA-4Antibodies MonoclonalCell BiologyHematologyHematopoietic Stem CellsChemokine CXCL12Peptide FragmentsRecombinant ProteinsCell biologyFibronectinsFibronectinchemistryLiverbiology.proteinStromal CellsChemokines CXCHoming (hematopoietic)Signal TransductionExperimental hematology
researchProduct

ACUTE VISION LOSS AS THE ONLY SIGN OF LEUKEMIA RELAPSE.

2016

Purpose To report a case of unilateral exudative retinal detachment as the sole presentation of relapsing B-type lymphoblastic leukemia in a 35-year-old man after 3 years of remission. Methods Case report. Results A 35-year-old man in complete remission of high-risk type B acute lymphoblastic leukemia (ALL-B) presented with acute vision loss in his left eye. Exudative retinal detachment was diagnosed at initial evaluation. Hematological and ocular studies were performed. Although there was no evidence of blood, cerebrospinal fluid, or bone marrow disease relapse, transvitreal retinochoroidal cytology identified the infiltration of lymphoblastic leukemic B cells with t(12:21) translocation a…

AdultMalemedicine.medical_specialtyVisual acuitymedicine.medical_treatmentBiopsyVisual AcuityVitrectomyAntineoplastic AgentsEndotamponadeBlindnessGastroenterology03 medical and health sciences0302 clinical medicineCerebrospinal fluidRecurrencehemic and lymphatic diseasesInternal medicineCytologyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaVitrectomyBiopsymedicineHumansSilicone OilsB Acute Lymphoblastic Leukemiamedicine.diagnostic_testbusiness.industryRetinal DetachmentMagnetic resonance imagingGeneral MedicineExudative retinal detachmentFlow CytometryMagnetic Resonance ImagingOphthalmology030220 oncology & carcinogenesisAcute Disease030221 ophthalmology & optometrymedicine.symptomInjections IntraocularbusinessRetinal casesbrief reports
researchProduct

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia

2013

Constitutional dominant loss-of-function mutations in the SPRED1 gene cause a rare phenotype referred as neurofibromatosis type 1 (NF1)-like syndrome or Legius syndrome, consisted of multiple café-au-lait macules, axillary freckling, learning disabilities and macrocephaly. SPRED1 is a negative regulator of the RAS MAPK pathway and can interact with neurofibromin, the NF1 gene product. Individuals with NF1 have a higher risk of haematological malignancies. SPRED1 is highly expressed in haematopoietic cells and negatively regulates haematopoiesis. SPRED1 seemed to be a good candidate for leukaemia predisposition or transformation. We performed SPRED1 mutation screening and expression status i…

MaleCancer ResearchAdolescentLoss of HeterozygosityFrameshift mutationGene productLoss of heterozygosityPrecursor B-Cell Lymphoblastic Leukemia-Lymphomahemic and lymphatic diseasesGeneticsmedicineHumansGenes Tumor SuppressorNeurofibromatosisChildMolecular BiologyAdaptor Proteins Signal TransducingLegius syndromeNeurofibromin 1biologyCafe-au-Lait SpotsInfant NewbornIntracellular Signaling Peptides and ProteinsMacrocephalyInfantMembrane Proteinsmedicine.diseaseNeurofibromin 1Gene Expression Regulation NeoplasticLeukemia Myeloid AcuteHaematopoiesisGenes rasChild PreschoolMutationCancer researchbiology.proteinFemalemedicine.symptomOncogene
researchProduct